Mentions
Extended reach
Total likes
Video views
AI synopsis
The collection of posts consistently emphasizes the significance of the FLOW trial, using phrases like 'substantially reduced risks' and 'significant reduction' to highlight the potential impact of semaglutide treatment on heart failure and cardiovascular outcomes. The tone, characterized by technical language and citations of specific statistics and analyses, underscores the high level of interest and perceived importance of this research within the medical community.
Most discussions emphasize the positive effects of semaglutide, highlighting significant reductions in heart failure events and cardiovascular death, showing strong consensus support.
The strong use of medical terminology, summaries of trial results, and references to specific analyses reflect high interest in the study's outcomes.
While many discussions elaborate on the results, some posts merely share the findings or cite sources without much critical analysis, indicating moderate but not deep engagement.
The frequent references to structured clinical trials, statistical findings, and clinical implications demonstrate that these discussions are viewed as potentially transformative for medical practice.
Con diabetes y enfermedad renal crónica G3A3, semaglutide 1.0mg semanal, comparado a placebo, ↓27% el evento cardiovascular y de falla cardiaca Se necesitan tratar 34 pacientes para ver 1 beneficiado En PostHoc del ensayo clínico FLOW JACC 2024 10.1016/j.jacc.2024.08.004 https://t.co/4zgmFJGIsC
FLOW trial: In participants with type 2 diabetes and chronic kidney disease, weekly semaglutide treatment substantially reduced risks of heart failure events or cardiovascular death. https://t.co/SaGx7tf0ie #JACC #ESCCongress #HeartFailure #T2D #CKD #Semaglutide #CVD @RpratleyMD https://t.co/imPxyGPsiD
#FLOW trial: In participants with type 2 #diabetes and #CKD, weekly #semaglutide treatment substantially reduced risks of #heartfailure events or CV death. https://t.co/OiUuD7Ryuz #JACC #T2D #Obesity @RpratleyMD @KatherineTuttl8 https://t.co/jdW23vIqfY
Swe the amazing Effects of Semaglutide on Heart Failure Outcomes in Diabetes and CKD https://t.co/kowNb62ye4 @Stenodiabetes https://t.co/PQDeDsMYhP
Effects of Semaglutide on Heart Failure Outcomes in Diabetes and CKD FLOW Trial Semaglutide reduced the risk of time to first composite outcome of HF events or CV death, as well as HF events and CV death alone, in high-risk population with T2D and CKD https://t.co/3UulKvZ2U5 https://t.co/bFxef1rRfr
Emerging evidence indicates that semaglutide, a treatment for type 2 diabetes, may protect against Alzheimer's disease, but more real-world data are needed. The study compared effects of semaglutide against other…
Neha J Pagidipati MD FACC and Richard Pratley MD discuss how the FLOW trial demonstrates that semaglutide significantly reduces heart failure events, cardiovascular death, and kidney failure in patients with diabetes…
4/ ❤️Semaglutide Reduces HF Events In T2D + CKD (FLOW), weekly sema ↓ HF events by 27% and CV death by 29%. ✅Benefits seen regardless of prior HF history.
The FLOW trial shows Semaglutide may improve heart failure outcomes in diabetes and chronic kidney disease patients. #HeartHealth #Diabetes #KidneyDisease https://t.co/zrGJZDsdl0 https://t.co/9ysUjpntbB
أظهرت تجربة FLOW أن Semaglutide قد يحسن نتائج فشل القلب في مرضى السكري ومرض الكلى المزمن. #صحة_القلب #السكري #مرض_الكلى https://t.co/SgKiAMlKQM https://t.co/rYuTtEiE2N
(3/7) In #JACC, Dr. @RpratleyMD and colleagues published a secondary analysis of FLOW looking at #semaglutide's impact on #heartfailure outcomes in this population https://t.co/NBXW1RBqQy https://t.co/eHAfJni5WX
Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW Trial | Journal of the American College of Cardiology https://t.co/XdAQuVW9Bi
RT @ZHeart11768530:
RT @JonathanNefro: Con diabetes y enfermedad renal crónica G3A3, semaglutide 1.0mg semanal, comparado a placebo, ↓27% el evento cardiovascu…
RT @JonathanNefro: Con diabetes y enfermedad renal crónica G3A3, semaglutide 1.0mg semanal, comparado a placebo, ↓27% el evento cardiovascu…
RT @JonathanNefro: Con diabetes y enfermedad renal crónica G3A3, semaglutide 1.0mg semanal, comparado a placebo, ↓27% el evento cardiovascu…
RT @JonathanNefro: Con diabetes y enfermedad renal crónica G3A3, semaglutide 1.0mg semanal, comparado a placebo, ↓27% el evento cardiovascu…
RT @JonathanNefro: Con diabetes y enfermedad renal crónica G3A3, semaglutide 1.0mg semanal, comparado a placebo, ↓27% el evento cardiovascu…
RT @JonathanNefro: Con diabetes y enfermedad renal crónica G3A3, semaglutide 1.0mg semanal, comparado a placebo, ↓27% el evento cardiovascu…
RT @JonathanNefro: Con diabetes y enfermedad renal crónica G3A3, semaglutide 1.0mg semanal, comparado a placebo, ↓27% el evento cardiovascu…
RT @JonathanNefro: Con diabetes y enfermedad renal crónica G3A3, semaglutide 1.0mg semanal, comparado a placebo, ↓27% el evento cardiovascu…
From the FLOWstudy:semaglutide Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chron... https://t.co/VZQmW3RpDb
RT @JonathanNefro: Con diabetes y enfermedad renal crónica G3A3, semaglutide 1.0mg semanal, comparado a placebo, ↓27% el evento cardiovascu…
RT @JonathanNefro: Con diabetes y enfermedad renal crónica G3A3, semaglutide 1.0mg semanal, comparado a placebo, ↓27% el evento cardiovascu…
RT @JonathanNefro: Con diabetes y enfermedad renal crónica G3A3, semaglutide 1.0mg semanal, comparado a placebo, ↓27% el evento cardiovascu…
RT @JonathanNefro: Con diabetes y enfermedad renal crónica G3A3, semaglutide 1.0mg semanal, comparado a placebo, ↓27% el evento cardiovascu…
RT @JonathanNefro: Con diabetes y enfermedad renal crónica G3A3, semaglutide 1.0mg semanal, comparado a placebo, ↓27% el evento cardiovascu…
RT @JonathanNefro: Con diabetes y enfermedad renal crónica G3A3, semaglutide 1.0mg semanal, comparado a placebo, ↓27% el evento cardiovascu…
RT @JonathanNefro: Con diabetes y enfermedad renal crónica G3A3, semaglutide 1.0mg semanal, comparado a placebo, ↓27% el evento cardiovascu…
RT @JonathanNefro: Con diabetes y enfermedad renal crónica G3A3, semaglutide 1.0mg semanal, comparado a placebo, ↓27% el evento cardiovascu…
RT @JonathanNefro: Con diabetes y enfermedad renal crónica G3A3, semaglutide 1.0mg semanal, comparado a placebo, ↓27% el evento cardiovascu…
RT @JonathanNefro: Con diabetes y enfermedad renal crónica G3A3, semaglutide 1.0mg semanal, comparado a placebo, ↓27% el evento cardiovascu…
RT @JonathanNefro: Con diabetes y enfermedad renal crónica G3A3, semaglutide 1.0mg semanal, comparado a placebo, ↓27% el evento cardiovascu…
RT @JonathanNefro: Con diabetes y enfermedad renal crónica G3A3, semaglutide 1.0mg semanal, comparado a placebo, ↓27% el evento cardiovascu…
RT @JonathanNefro: Con diabetes y enfermedad renal crónica G3A3, semaglutide 1.0mg semanal, comparado a placebo, ↓27% el evento cardiovascu…
Con diabetes y enfermedad renal crónica G3A3, semaglutide 1.0mg semanal, comparado a placebo, ↓27% el evento cardiovascular y de falla cardiaca Se necesitan tratar 34 pacientes para ver 1 beneficiado En PostHoc del ensayo clínico FLOW JACC 2024 10.1016/j.jacc.2024.08.004 https://t.co/4zgmFJGIsC
RT @drbennisahmed: Effects of Semaglutide on Heart Failure Outcomes in Diabetes and CKD FLOW Trial Semaglutide reduced the risk of time t…
RT @ZHeart11768530:
RT @drbennisahmed: Effects of Semaglutide on Heart Failure Outcomes in Diabetes and CKD FLOW Trial Semaglutide reduced the risk of time t…
Effects of Semaglutide on Heart Failure Outcomes in Diabetes and CKD FLOW Trial Semaglutide reduced the risk of time to first composite outcome of HF events or CV death, as well as HF events and CV death alone, in high-risk population with T2D and CKD https://t.co/3UulKvZ2U5 https://t.co/bFxef1rRfr
RT @JACCJournals: #FLOW trial: In participants with type 2 #diabetes and #CKD, weekly #semaglutide treatment substantially reduced risks of…
RT @JACCJournals: #FLOW trial: In participants with type 2 #diabetes and #CKD, weekly #semaglutide treatment substantially reduced risks of…
RT @JACCJournals: #FLOW trial: In participants with type 2 #diabetes and #CKD, weekly #semaglutide treatment substantially reduced risks of…
RT @JACCJournals: #FLOW trial: In participants with type 2 #diabetes and #CKD, weekly #semaglutide treatment substantially reduced risks of…
RT @JACCJournals: #FLOW trial: In participants with type 2 #diabetes and #CKD, weekly #semaglutide treatment substantially reduced risks of…
RT @JACCJournals: #FLOW trial: In participants with type 2 #diabetes and #CKD, weekly #semaglutide treatment substantially reduced risks of…
#FLOW trial: In participants with type 2 #diabetes and #CKD, weekly #semaglutide treatment substantially reduced risks of #heartfailure events or CV death. https://t.co/OiUuD7Ryuz #JACC #T2D #Obesity @RpratleyMD @KatherineTuttl8 https://t.co/jdW23vIqfY
Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW Trial
eg here they hint at it but I don’t know enough medicine to parse it out: https://t.co/9pfqAArkUp https://t.co/gn8B6BIVrb
RT @P_Rossing: Swe the amazing Effects of Semaglutide on Heart Failure Outcomes in Diabetes and CKD https://t.co/kowNb62ye4 @Stenodiabetes…
「CV死亡」のみでも0.71 [0.56-0.89]。 https://t.co/o6izbWQ7Cj
RT @JACCJournals: FLOW trial: In participants with type 2 diabetes and chronic kidney disease, weekly semaglutide treatment substantially r…
RT @ZHeart11768530:
https://t.co/lVzg5B0AaE
RT @JACCJournals: FLOW trial: In participants with type 2 diabetes and chronic kidney disease, weekly semaglutide treatment substantially r…
RT @JACCJournals: FLOW trial: In participants with type 2 diabetes and chronic kidney disease, weekly semaglutide treatment substantially r…
RT @JACCJournals: FLOW trial: In participants with type 2 diabetes and chronic kidney disease, weekly semaglutide treatment substantially r…
Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chron... https://t.co/AUhIPS78jh Just presented at #ESC and published in #JACC - semaglutide decreased risk of heart failure and CV death by 27% in the FLOW trial in T2D and CVD.
RT @JACCJournals: FLOW trial: In participants with type 2 diabetes and chronic kidney disease, weekly semaglutide treatment substantially r…
Swe the amazing Effects of Semaglutide on Heart Failure Outcomes in Diabetes and CKD https://t.co/kowNb62ye4 @Stenodiabetes https://t.co/PQDeDsMYhP
RT @JACCJournals: FLOW trial: In participants with type 2 diabetes and chronic kidney disease, weekly semaglutide treatment substantially r…
RT @JACCJournals: FLOW trial: In participants with type 2 diabetes and chronic kidney disease, weekly semaglutide treatment substantially r…
FLOW trial: In participants with type 2 diabetes and chronic kidney disease, weekly semaglutide treatment substantially reduced risks of heart failure events or cardiovascular death. https://t.co/SaGx7tf0ie #JACC #ESCCongress #HeartFailure #T2D #CKD #Semaglutide #CVD @RpratleyMD https://t.co/imPxyGPsiD
doi.org/10.1016/j.annemergmed.2024.08.004. any gastric air that may ... jacc.2020.05.074. and procedural guidance. Accessed October 26, 2024. https ...
Liu). Trends in Endocrinology & Metabolism, Month 2024, Vol. xx, No. xx https://doi.org/10.1016/j.tem.2024.08.004 1 ... JACC kappaB activation. Aging Cell ...
doi:10.1016/j.jacc.2024.08.004. Kittipibul V, Mentz RJ. Effects of ... J Am Coll Cardiol. 2024 Aug 24:S0735-1097(24)08168-3. doi:10.1016 ...
... (JACC) et présentées lors du congrès 2024 de l'European Society. ... 10.1016/j.jacc.2024.08.004 Effects of Semaglutide on Heart Failure ...
JACC Basic Transl. Sci.4,940–958 (2019). Crossref · PubMed · Web ... https://doi.org/10.1016/j.ccm.2024.08.004 · Crossref. Gang Liu,; Bin-bin ...
JC
JJ
TH
PR
AM
MⲂ
HN
أا
A
BM
MF
RG
NG
DB
JO
EA
LA
D
L
HG
C
VP
J
SH
FM
DE
AK
SV
JE
DA
M
DN
JR
SA
UC
DL
Tね
EE
糸潤
CM
JF
SC
I
KT
宇T
DS
DR
S
DC
PC
RM
CM
SZ
BN